Marine Biomedical was proud to host the Joint Standing Committee on Northern Australia this week as part of their inquiry into preparing Northern Australia for emerging industries. The visit was an important opportunity to connect directly with decision‑makers and highlight the work we’re doing to build a world‑class biomedical manufacturing capability in northern WA.

Marine Biomedical today announced the submission of its 510(k) application to the United States Food and Drug Administration (FDA) for PearlBone™, the Company’s first marine-derived bone graft substitute.

Marine Biomedical has entered into a strategic investment and commercial arrangement with Orthocell, strengthening the company’s position as it prepares to advance its first product, PearlBone™, toward market entry.

In an exhilarating culmination of breakthrough research, development, and dedication, Marine Biomedical is now at the forefront of the biomedical innovation sector.